Kris Cameron Wood

Associate Professor of Pharmacology and Cancer Biology

Appointments and Affiliations

• Associate Professor of Pharmacology and Cancer Biology
• Core Faculty in Innovation & Entrepreneurship
• Member of the Duke Cancer Institute

Contact Information

• Email Address: kris.wood@duke.edu
• Websites:
  • Wood Lab

Education

• Ph.D. Massachusetts Institute of Technology, 2007
• B.S. University of Kentucky, Lexington, 2002

Research Interests

More effective anticancer therapeutic strategies, many of which are based on functional genomics. Examples of projects include: a miniaturized screening platform, tools to systematically map the signaling pathways controlling anticancer drug responses, high-throughput computational methods to discover anticancer drug combinations, design of therapeutic strategies to reverse or prevent drug resistance, and systematic credentialing of mutations uncovered through cancer genome sequencing projects.

Courses Taught

• CMB 710E: Cell & Molecular Biology Module V
• MOLCAN 818: Molecular Mechanisms of Oncogenesis
• PHARM 393: Research Independent Study
• PHARM 394: Research Independent Study
• PHARM 493: Research Independent Study
• PHARM 494: Research Independent Study
• PHARM 495: Research Independent Study
• PHARM 818: Molecular Mechanisms of Oncogenesis
• UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I

In the News

• Cancer Therapy Using Genetic Targeting and Gel Delivery Shows Promise (Sep 16, 2019 | Pratt School of Engineering)
• From Innovation to Impact (Oct 3, 2018 | Duke Med Alumni News)
• Faculty Startup Sold to Belgian Pharma for $30 Million (Apr 9, 2018)
• Why Do Perfectly Good Cancer Treatments Suddenly Stop Working? (Oct 25, 2017 | Duke Cancer Institute)
• The Challenges of Combating Cancer Drug Resistance (Nov 19, 2015 | Duke Research Blog)
• Researchers Map Paths to Cancer Drug Resistance (Jan 5, 2015)

Representative Publications

• Garcia, N; Del Pozo, V; Yohe, ME; Goodwin, CM; Shackleford, TJ; Wang, L; Baxi, K; Chen, Y; Rogojina, AT; Zimmerman, SM; Peer, CJ; Figg, WD; Ignatius, MS; Wood, KC; Houghton, PJ; Vaseva, AV, Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma., Mol Cancer Ther (2021) [10.1158/1535-7163.MCT-21-0194] [abs].
• Luttman, JH; Hoj, JP; Lin, KH; Lin, J; Gu, JJ; Rouse, C; Nichols, AG; MacIver, NJ; Wood, KC; Pendergast, AM, ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells., Cell Reports, vol 37 no. 4 (2021) [10.1016/j.celrep.2021.109880] [abs].
• Joh, DY; Heggestad, JT; Zhang, S; Anderson, GR; Bhattacharyya, J; Wardell, SE; Wall, SA; Cheng, AB; Albarghouthi, F; Liu, J; Oshima, S; Hucknall, AM; Hyslop, T; Hall, AHS; Wood, KC; Shelley Hwang, E; Strickland, KC; Wei, Q; Chilkoti, A, Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates., Npj Breast Cancer, vol 7 no. 1 (2021) [10.1038/s41523-021-00335-4] [abs].
• Yellen, BB; Zawistowski, JS; Czech, EA; Sanford, CI; SoRelle, ED; Luftig, MA; Forbes, ZG; Wood, KC; Hammerbacher, J, Massively parallel quantification of phenotypic heterogeneity in single-cell drug responses., Science Advances, vol 7 no. 38 (2021) [10.1126/sciadv.abf9840] [abs].
• Joh, DY; Heggestad, JT; Zhang, S; Anderson, GR; Bhattacharyya, J; Wardell, SE; Wall, SA; Cheng, AB; Albarghouthi, F; Liu, J; Oshima, S; Hucknall, AM; Hyslop, T; Hall, AHS; Wood, KC; Shelley Hwang, E; Strickland, KC; Wei, Q; Chilkoti, A, Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates., Npj Breast Cancer, vol 7 no. 1 (2021) [10.1038/s41523-021-00290-0] [abs].